Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2− Metastatic Breast Cancer

被引：0
|
作者：
Annie Guérin
Debbie Goldschmidt
Tania Small
Patrick Gagnon-Sanschagrin
Hela Romdhani
Genevieve Gauthier
Sneha Kelkar
Eric Q. Wu
Polly Niravath
Anand A. Dalal
机构：
[1] Analysis Group,
[2] Inc.,undefined
[3] Analysis Group,undefined
[4] Inc.,undefined
[5] Novartis Pharmaceuticals Corporation,undefined
[6] Analysis Group,undefined
[7] Inc.,undefined
[8] Houston Methodist Hospital,undefined
来源：
Advances in Therapy | 2018年 / 35卷
关键词：
CDK4/6 inhibitor; HR+/HER2−; Metastatic breast cancer; Monitoring; Oncology; Post-menopausal;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1251 / 1264
页数：13
相关论文
共 50 条
  • [21] Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis
    Li, Nanxin
    Hao, Yanni
    Koo, Valerie
    Fang, Anna
    Peeples, Miranda
    Kageleiry, Andrew
    Wu, Eric Q.
    Guerin, Annie
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (04) : 414 - 423
  • [22] Impact of molecular subtype and race on HR+, HER2− breast cancer survival
    Sonya Reid
    Diane Haddad
    Ann Tezak
    Anne Weidner
    Xuefeng Wang
    Brian Mautz
    Jaleesa Moore
    Sydney Cadiz
    Yuwei Zhu
    Wei Zheng
    Ingrid A. Mayer
    Xiao-ou Shu
    Tuya Pal
    Breast Cancer Research and Treatment, 2021, 189 : 845 - 852
  • [23] Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women
    Geneviève Gauthier
    Patrick Gagnon-Sanschagrin
    Annie Guérin
    Rebecca Burne
    Tania Small
    Polly Niravath
    Anand A. Dalal
    Advances in Therapy, 2018, 35 : 503 - 514
  • [24] Treatment patterns and sequences among pre-menopausal women with HR+/HER2-metastatic breast cancer: A chart review study
    Dalal, A. A.
    Goldschmidt, D.
    Romdhani, H.
    Kelkar, S.
    Guerin, A.
    Wang, H.
    Caria, N.
    Sawhney, A.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [25] Economic Burden of HR+/HER2-Metastatic Breast Cancer Among Adult Premenopausal Women
    Gauthier, Genevieve
    Gagnon-Sanschagrin, Patrick
    Guerin, Annie
    Burne, Rebecca
    Small, Tania
    Niravath, Polly
    Dalal, Anand A.
    ADVANCES IN THERAPY, 2018, 35 (04) : 503 - 514
  • [26] Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
    Hope S. Rugo
    Peter Kabos
    J. Thad Beck
    Guy Jerusalem
    Hans Wildiers
    Elena Sevillano
    Luis Paz-Ares
    Michael J. Chisamore
    Sonya C. Chapman
    Anwar M. Hossain
    Yanyun Chen
    Sara M. Tolaney
    npj Breast Cancer, 8
  • [27] SOCIETAL COSTS OF ER+/HER2-ADVANCED OR METASTATIC BREAST CANCER IN POST-MENOPAUSAL WOMEN IN THE UNITED KINGDOM
    Bermingham, S.
    Schmid, P.
    Forster, F.
    Comic, L.
    Theti, D.
    Smith, A.
    VALUE IN HEALTH, 2017, 20 (09) : A427 - A427
  • [28] Evolving perspectives on the treatment of HR+/HER2+metastatic breast cancer
    Pegram, Mark
    Pietras, Richard
    Dang, Chau T.
    Murthy, Rashmi
    Bachelot, Thomas
    Janni, Wolfgang
    Sharma, Priyanka
    Hamilton, Erika
    Saura, Cristina
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [29] WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN WOMEN WITH HR+/HER2-ADVANCED/ METASTATIC BREAST CANCER
    Wood, R.
    Mitra, D.
    DeCourcy, J.
    Iyer, S.
    VALUE IN HEALTH, 2017, 20 (05) : A123 - A123
  • [30] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
12345